Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 + Adebrelimab Maintenance in ES-SCLC
NCT07063407Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jul 2025
- Primary completion
- Apr 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 1, open-label, single-arm trial of risvutatug rezetecan in small cell lung cancer (SCLC), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Progression-Free Survival at 24 months. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07063407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07063407.